Effect of Vortioxetine on Cognitive Impairment in Patients With Major Depressive Disorder: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Open accessThe DOI matches its Crossref record; 52 of the 53 references it cites were found in a registry or an index.
Abstract
Background: Dementia and depression are increasingly common worldwide, and their effective control could ease the burden on economies, public health systems, and support networks. Vortioxetine is a new antidepressant with multipharmacologic actions that elevate the concentration of serotonin and modulate multiple neurotransmitter receptors in the brain. We conducted a meta-analysis to explore whether the cognitive function of patients with major depressive disorder (MDD) treated with vortioxetine would improve. Methods: We systematically reviewed randomized controlled trials (RCTs) in the PubMed, Embase, and Cochrane databases to assess the treatment effects of vortioxetine on the cognitive function of patients with MDD. The outcome measures included the Digit Symbol Substitution Test (DSST), Perceived Deficits Questionnaire (PDQ), and Montgomery-Åsberg Depression Rating Scale (MADRS) scores. Pooled results were calculated using a fixed-effects or random-effects model according to the heterogeneity of the included trials. Results: Six RCTs with a total of 1782 patients were included in the meta-analysis, which demonstrated that vortioxetine improved DSST, PDQ, and MADRS scores in patients with MDD. The results were consistent at the 10- and 20-mg doses. In the 20-mg group, the decrease in MADRS scores was more significant than that in the placebo group. Conclusions: Both the 10- and 20-mg doses of vortioxetine can significantly increase DSST scores and decrease PDQ and MADRS scores in patients with MDD and cognitive dysfunction, but further studies with longer follow-up periods to assess mental function are required.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Dementia prevention, intervention, and care: 2020 report of the Lancet Commission
Livingston, G., Huntley, J., Sommerlad, A., Ames, D., Ballard, C., Banerjee, S., Brayne, C., Burns, A., Cohen-Mansfield, J., Cooper, C., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30367-6 · Cited by 10,430 · cited 7×
“Three RCTs reported data on MADRS scores (McIntyre et al., 2014; Mahableshwarkar et al., 2015; Inoue et al., 2020).”
BackgroundInfluentialRetractedDiagnostic and Statistical Manual of Mental Disorders
American Psychiatric Association (2013) · doi:10.1176/appi.books.9780890425596 · Cited by 116,369
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552 · cited 1×
“We used a random-effects model (DerSimonian and Laird, 1986) to pool the estimates according to the presence or absence of heterogeneity.”
MethodCochrane Handbook for Systematic Reviews of Interventions
(2019) · doi:10.1002/9781119536604 · Cited by 14,828
Zhang, Q., Wang, C., Zheng, M., Li, Y., Li, J., Zhang, L., Shang, X., & Yan, C. (2015) · Cerebrovascular Diseases · doi:10.1159/000369778 · Cited by 11,533
Projections of Global Mortality and Burden of Disease from 2002 to 2030
Mathers, C. D., & Loncar, D. (2006) · PLoS Medicine · doi:10.1371/journal.pmed.0030442 · Cited by 11,386
From inflammation to sickness and depression: when the immune system subjugates the brain
Dantzer, R., O'Connor, J. C., Freund, G. G., Johnson, R. W., & Kelley, K. W. (2008) · Nature Reviews Neuroscience · doi:10.1038/nrn2297 · Cited by 7,395 · cited 1×
“Furthermore, immune dysregulation, such as increased proinflammatory cytokines interleukin-1b, tumor necrosis factor-ɑ, and interferons, were also noticed in depressed human and animal models (Dantzer et al., 2008; Wohleb et al., 2016).”
BackgroundCumpston, M., Li, T., Page, M. J., Chandler, J., Welch, V. A., Higgins, J. P., & Thomas, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.ed000142 · Cited by 7,218
McGuinness, L. A., & Higgins, J. P. T. (2021) · Research Synthesis Methods · doi:10.1002/jrsm.1411 · Cited by 5,579 · cited 6×
“Three RCTs reported data on MADRS scores (McIntyre et al., 2014; Mahableshwarkar et al., 2015; Inoue et al., 2020).”
BackgroundInfluentialDiniz, B. S., Butters, M. A., Albert, S. M., Dew, M. A., & Reynolds, C. F. (2013) · British Journal of Psychiatry · doi:10.1192/bjp.bp.112.118307 · Cited by 1,290 · cited 1×
“Diniz et al. (2013) found a link between depression in older adults (adults aged above 65-year-old) and the risk of dementia, including both Alzheimer disease and vascular dementia.”
BackgroundDepression and risk of developing dementia
Byers, A. L., & Yaffe, K. (2011) · Nature Reviews Neurology · doi:10.1038/nrneurol.2011.60 · Cited by 1,265 · cited 2×
“The pathophysiologic changes of cognitive impairment in MDD are related to serotonin (5-HT) depletion (Štrac et al., 2016) and hippocampus injury secondary to hypothalamic-pituitaryadrenal axis–induced glucocorticoid elevation (Byers and Yaffe, 2011).”
BackgroundThe Maudsley Prescribing Guidelines in Psychiatry
Taylor, D. M., Barnes, T. R. E., & Young, A. H. (2021) · Wiley eBooks · doi:10.1002/9781119870203 · Cited by 988 · cited 1×
“The current guidelines for depression treatment focus less on the treatment of cognitive conditions (McQuaid, 2019; Taylor et al., 2021; The National Institute for Health and Care Excellence, 2021).”
MethodJaeger, J. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000941 · Cited by 836 · cited 1×
“Multiple cognitive domains, such as executive function, working memory, attention, and motor speed, are assessed in the DSST (Jaeger, 2018).”
MethodIntegrating neuroimmune systems in the neurobiology of depression
Wohleb, E. S., Franklin, T., Iwata, M., & Duman, R. S. (2016) · Nature Reviews Neuroscience · doi:10.1038/nrn.2016.69 · Cited by 668 · cited 1×
“Furthermore, immune dysregulation, such as increased proinflammatory cytokines interleukin-1b, tumor necrosis factor-ɑ, and interferons, were also noticed in depressed human and animal models (Dantzer et al., 2008; Wohleb et al., 2016).”
BackgroundDepression and dementia: cause, consequence or coincidence?
Bennett, S., & Thomas, A. J. (2014) · Maturitas · doi:10.1016/j.maturitas.2014.05.009 · Cited by 569 · cited 1×
“Studies have concluded that both early- and late-life depression had associations with dementia in the general population, not only in geriatrics (Kessing et al., 2009 ; Bennett and Thomas, 2014).”
BackgroundMcIntyre, R. S., Lophaven, S., & Olsen, C. K. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000546 · Cited by 433 · cited 1×
“…various antidepressant agents thus far assessed, evidence for a positive, direct effect across multiple cognitive domains is strong for vortioxetine but relatively weak for other SSRI agents, serotonin-norepinephrine reuptake inhibitors, or bupropion (Jensen et al., 2014; McIntyre et al., 2015).”
BackgroundDepression in adults: recognition and management
(2017) · Clinical Pharmacist · doi:10.1211/cp.2017.20202439 · Cited by 393
Cognitive impairment in depression: recent advances and novel treatments
Perini, G., Cotta Ramusino, M., Sinforiani, E., Bernini, S., Petrachi, R., & Costa, A. (2019) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s199746 · Cited by 384 · cited 1×
“Overall, the studies supported vortioxetine as the first antidepressant drug to demonstrate proven efficacy in improving the cognitive symptoms of depression (Perini et al., 2019).”
ResultRosenblat, J. D., Kakar, R., & McIntyre, R. S. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyv082 · Cited by 315 · cited 2×
“McIntyre et al. concluded that vortioxetine had a significant positive effect on psychomotor speed and delayed recall (Rosenblat et al., 2016).”
BackgroundMahableshwarkar, A. R., Zajecka, J., Jacobson, W., Chen, Y., & Keefe, R. S. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.52 · Cited by 307 · cited 1×
“It is estimated to affect 340 million people globally and is expected to be the leading cause of disability-adjusted life-years in high-income countries by 2030 (Mathers and Loncar, 2006).”
BackgroundThe serotonergic system and cognitive function
Švob Štrac, D., Pivac, N., & Mück-Šeler, D. (2016) · Translational Neuroscience · doi:10.1515/tnsci-2016-0007 · Cited by 285 · cited 1×
“The current guidelines for depression treatment focus less on the treatment of cognitive conditions (McQuaid, 2019; Taylor et al., 2021; The National Institute for Health and Care Excellence, 2021).”
MethodBartels, C., Wagner, M., Wolfsgruber, S., Ehrenreich, H., Schneider, A., & Initiative, F. T. A. D. N. (2018) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2017.17040404 · Cited by 202 · cited 1×
“Bartels et al. (2018) suggested that using SSRI to treat patients with depression for more than 4 years was associated with a delay in cognitive dysfunction.”
MethodBaldwin, D. S., Chrones, L., Florea, I., Nielsen, R., Nomikos, G. G., Palo, W., & Reines, E. (2016) · Journal of Psychopharmacology · doi:10.1177/0269881116628440 · Cited by 187 · cited 1×
“In 2 studies on the long-term use of vortioxetine (Jacobsen et al., 2015; Baldwin et al., 2016), the adverse events reported were the same as those in the short-term clinical trials, with no significant changes in patient body weight, vital signs, or laboratory data after 52-week trials.”
ResultMcIntyre, R., Harrison, J., Loft, H., Jacobson, W., & Olsen, C. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw055 · Cited by 185 · cited 1×
“…u lt ip le c ou n tr ie s: A u st ra li a, C an ad a, F in la n d , F ra n ce , G er m an y, L at vi a, M ex ic o, S er bi a, S lo va ki a, S ou th A fr ic a, U kr ai n e, a n d t h e U n it ed S ta te s. its efficacy on self-rated cognitive deficits and employment position (McIntyre et al., 2017).”
Thase, M. E., Mahableshwarkar, A. R., Dragheim, M., Loft, H., & Vieta, E. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.03.007 · Cited by 162 · cited 1×
“The meta-analysis of vortioxetine by Thase et al. (2016) demonstrated a general dose-dependent trend in improvements in MADRS scores.”
MethodMcIntyre, R. S., Xiao, H. X., Syeda, K., Vinberg, M., Carvalho, A. F., Mansur, R. B., Maruschak, N., & Cha, D. S. (2015) · CNS Drugs · doi:10.1007/s40263-015-0263-x · Cited by 145 · cited 1×
“The meta-analysis by McIntyre et al. (2016) of 3 RCTs demonstrated that changes in DSST scores statistically favored vortioxetine compared with duloxetine and placebo (P = .04 and P < .001, respectively) after adjustments for MADRS scores, indicating that the improvement effect of vortioxetine on…”
MethodDepression in adults: recognition and management
(2017) · Pharmaceutical journal/The pharmaceutical journal · doi:10.1211/pj.2017.20202439 · Cited by 138
Chan, J. Y. C., Yiu, K. K. L., Kwok, T. C. Y., Wong, S. Y. S., & Tsoi, K. K. F. (2019) · Journal of the American Medical Directors Association · doi:10.1016/j.jamda.2018.12.004 · Cited by 135
Kessing, L. V., Søndergård, L., Forman, J. L., & Andersen, P. K. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2008.11.020 · Cited by 113
Vortioxetine (brintellix): a new serotonergic antidepressant.
(2015) · PubMed Central · Cited by 112
Moraros, J., Nwankwo, C., Patten, S. B., & Mousseau, D. D. (2017) · Depression and Anxiety · doi:10.1002/da.22584 · Cited by 105 · cited 1×
“Overall, the studies supported vortioxetine as the first antidepressant drug to demonstrate proven efficacy in improving the cognitive symptoms of depression (Perini et al., 2019).”
ResultEfficacy of Vortioxetine on Cognitive Functioning in Working Patients With Major Depressive Disorder
McIntyre, R. S., Florea, I., Tonnoir, B., Loft, H., Lam, R. W., & Christensen, M. C. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m10744 · Cited by 100 · cited 2×
“…2009; Moraros et al., 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
BackgroundResultWallace, A., Pehrson, A. L., Sánchez, C., & Morilak, D. A. (2014) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145714000571 · Cited by 97 · cited 1×
“Vortioxetine has provided evidence of improved cognitive function (Jensen et al., 2014; Wallace et al., 2014; Al-Sukhni et al., 2015; McQuaid, 2019).”
BackgroundJensen, J. B., du Jardin, K. G., Song, D., Budac, D., Smagin, G., Sanchez, C., & Pehrson, A. L. (2014) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2013.10.011 · Cited by 96 · cited 3×
“…various antidepressant agents thus far assessed, evidence for a positive, direct effect across multiple cognitive domains is strong for vortioxetine but relatively weak for other SSRI agents, serotonin-norepinephrine reuptake inhibitors, or bupropion (Jensen et al., 2014; McIntyre et al., 2015).”
BackgroundSmith, J., Browning, M., Conen, S., Smallman, R., Buchbjerg, J., Larsen, K. G., Olsen, C. K., Christensen, S. R., Dawson, G. R., Deakin, J. F., et al. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.104 · Cited by 89 · cited 1×
“The pathophysiologic changes of cognitive impairment in MDD are related to serotonin (5-HT) depletion (Štrac et al., 2016) and hippocampus injury secondary to hypothalamic-pituitaryadrenal axis–induced glucocorticoid elevation (Byers and Yaffe, 2011).”
BackgroundVortioxetine for cognitive enhancement in major depression: From animal models to clinical research
Bennabi, D., Haffen, E., & Van Waes, V. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00771 · Cited by 75 · cited 1×
“Vortioxetine can influence multiple cognitive domains, such as attention, orientation, executive function and concentration (Harrison et al., 2016; Bennabi et al., 2019; Cumbo et al., 2019).”
BackgroundBaune, B. T., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.12.056 · Cited by 73 · cited 5×
“Two of the trials failed to mention safety issues or side effects (Baune et al., 2018; Smith et al., 2018).”
BackgroundInfluentialVieta, E., Sluth, L. B., & Olsen, C. K. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.11.053 · Cited by 72 · cited 1×
“Another RCT directly compared vortioxetine with escitalopram in relation to cognition and depressive symptoms; although the results were not statistically significant, numerical improvements across DSST, PDQ, and MADRS scores generally favored vortioxetine (Vieta et al., 2018).”
ResultAntidepressant use in the elderly is associated with an increased risk of dementia
Wang, C., Gao, S., Hendrie, H. C., Kesterson, J., Campbell, N. L., Shekhar, A., & Callahan, C. M. (2016) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0000000000000103 · Cited by 68 · cited 2×
“, 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
BackgroundResultExposure to Antidepressant Medication and the Risk of Incident Dementia
Kodesh, A., Sandin, S., Reichenberg, A., Rotstein, A., Pedersen, N. L., Ericsson, M., Karlsson, I. K., Davidson, M., & Levine, S. Z. (2019) · The American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2019.05.019 · Cited by 63 · cited 1×
“…2009; Moraros et al., 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
ResultWhich cognitive domains are improved by treatment with vortioxetine?
Harrison, J. E., Lophaven, S., & Olsen, C. K. (2016) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyw054 · Cited by 59 · cited 2×
“Vortioxetine can influence multiple cognitive domains, such as attention, orientation, executive function and concentration (Harrison et al., 2016; Bennabi et al., 2019; Cumbo et al., 2019).”
BackgroundMethodAl-Sukhni, M., Maruschak, N. A., & McIntyre, R. S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1046836 · Cited by 58 · cited 1×
“Vortioxetine has provided evidence of improved cognitive function (Jensen et al., 2014; Wallace et al., 2014; Al-Sukhni et al., 2015; McQuaid, 2019).”
BackgroundCumbo, E., Cumbo, S., Torregrossa, S., & Migliore, D. (2019) · The Journal of Prevention of Alzheimer's Disease · doi:10.14283/jpad.2019.24 · Cited by 57 · cited 1×
“Vortioxetine can influence multiple cognitive domains, such as attention, orientation, executive function and concentration (Harrison et al., 2016; Bennabi et al., 2019; Cumbo et al., 2019).”
BackgroundAntidepressant Use and Cognitive Decline: The Health and Retirement Study
Saczynski, J. S., Rosen, A. B., McCammon, R. J., Zivin, K., Andrade, S. E., Langa, K. M., Vijan, S., Pirraglia, P. A., & Briesacher, B. A. (2015) · The American Journal of Medicine · doi:10.1016/j.amjmed.2015.01.007 · Cited by 56 · cited 2×
“In 1 study, antidepressant agents were unable to modify the course of cognitive changes (Saczynski et al., 2015); another study, focused on a population of older women, concluded that the use of antidepressants, especially selective serotonin reuptake inhibitors (SSRIs) and trazodone, was associated with an increased…”
BackgroundChokka, P., Bougie, J., Proulx, J., Tvistholm, A. H., & Ettrup, A. (2019) · CNS Spectrums · doi:10.1017/s1092852919000786 · Cited by 56
Goveas, J. S., Hogan, P. E., Kotchen, J. M., Smoller, J. W., Denburg, N. L., Manson, J. E., Tummala, A., Mysiw, W. J., Ockene, J. K., Woods, N. F., et al. (2012) · International Psychogeriatrics · doi:10.1017/s1041610211002778 · Cited by 54 · cited 1×
“…2009; Moraros et al., 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
ResultAntidepressant Use and Cognitive Outcomes in Very Old Women
Leng, Y., Diem, S. J., Stone, K. L., & Yaffe, K. (2018) · The Journals of Gerontology: Series A · doi:10.1093/gerona/glx226 · Cited by 48 · cited 2×
“…2009; Moraros et al., 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
BackgroundResultChokka, P., Bougie, J., Rampakakis, E., & Proulx, J. (2019) · CNS Spectrums · doi:10.1017/s1092852918000913 · Cited by 48
Inoue, T., Sasai, K., Kitagawa, T., Nishimura, A., & Inada, I. (2020) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12956 · Cited by 45
Levada, O. A., & Troyan, A. S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.03.040 · Cited by 37 · cited 5×
“We had assessed the quality of the included studies, and there are some concerns in the bias in randomization of 1 RCT (Levada and Troyan, 2019) because there was lack of blinding for the assessments and no follow-up data from a healthy control group.”
BackgroundMethodInfluentialThen, C.-K., Chi, N.-F., Chung, K.-H., Kuo, L., Liu, K.-H., Hu, C.-J., Shen, S.-C., & Lin, Y.-K. (2017) · PLOS ONE · doi:10.1371/journal.pone.0175187 · Cited by 35 · cited 2×
“, 2017), but other studies have demonstrated that antidepressant use is associated with an increased risk of developing cognitive impairment and dementia (Goveas et al., 2012; Wang et al., 2016; Moraros et al., 2017; Then et al., 2017; Leng et al., 2018; Kodesh et al., 2019).”
BackgroundResultJacobsen, P. L., Harper, L., Chrones, L., Chan, S., & Mahableshwarkar, A. R. (2015) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000081 · Cited by 29
Research works printed but not linked: 4
- American Psychiatric Association, 2013, Neurocognitive disorders., 591
- Butterworth, 2020, Guidelines for the pharmacological management of dementia, p., 17
- McQuaid, 2019, APA Guideline for the Treatment of Depression; chap: discussion of clinical recommendations, 39
- World Health Organization, 2021, Dementia
Cited by
Depression in Alzheimer’s Disease: Epidemiology, Mechanisms, and Treatment
Huang, Y.-Y., Gan, Y.-H., Yang, L., Cheng, W., & Yu, J.-T. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2023.10.008 · Cited by 164
Rhee, T. G., Shim, S. R., Manning, K. J., Tennen, H. A., Kaster, T. S., d’Andrea, G., Forester, B. P., Nierenberg, A. A., McIntyre, R. S., & Steffens, D. C. (2024) · Psychotherapy and Psychosomatics · doi:10.1159/000535665 · Cited by 101
“While one meta-analysis suggested that antidepressants, particularly SSRIs, may improve multiple domains of cognition in adults with MDD [68], some studies [69, 70] suggested differential effects of antidepressants on cognition, requiring further research.”
Christensen, M. C., Schmidt, S. N., & Grande, I. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.06.024 · Cited by 39
Steardo, L., D’Angelo, M., Monaco, F., Stefano, V. D., & Steardo, L. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106030 · Cited by 46
Nicola, M. D., Pepe, M., Montanari, S., Spera, M. C., Panaccione, I., Simonetti, A., & Sani, G. (2023) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2023.02.006 · Cited by 27
Metadata
- Authors
- Huang, I.-C., Chang, T.-S., Chen, C., & Sung, J.-Y.
- Affiliations
- Wan Fang Hospital (TW)
- Corresponding author
- Sung, Jia-Ying
- Venue
- International Journal of Neuropsychopharmacology
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-19
- Volume
- 25
- Issue
- 12
- Pages
- 969-978
- ISSN
- 1461-1457 (ISSN-L)
- 1469-5111
- PMC
- PMC9743961
- OpenAlex
- W4293790530
- Cited by
- 41
- References
- 53
- Citations by year
- 2026: 8 · 2025: 16 · 2024: 11 · 2023: 6
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- The International Journal of Neuropsychopharmacology (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Funders
- Wan Fang Hospital, Taipei Medical University (110TMU-WFH-13)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- vortioxetine, major depressive disorder, cognitive impairment, cognitive function, antidepressants, serotonin, Digit Symbol Substitution Test, Montgomery-Asberg Depression Rating Scale, dose comparison
- MeSH terms
- Vortioxetine, Depressive Disorder, Major, Major Depressive Disorder, Double-Blind Method, Humans, Piperazines, Sulfides, Randomized Controlled Trials as Topic, Treatment Outcome, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.